



PIIL:SEC:NSE/BSE:36:2025-26
August 14, 2025

BSE Limited Corporate Relationship Department PJ Towers, 25 th Floor, Dalal Street, Mumbai – 400 001 Code No.523642	National Stock Exchange of India Ltd. Exchange Plaza, Plot No.C/1, G-Block Bandra Kurla Complex, Bandra (East), Mumbai – 400 051 Code No. PIIND
---	--

Dear Sir/ Ma'am,

Sub: Summary of the proceedings of the 78th Annual General Meeting ('e-AGM') of the Company held on August 14, 2025

Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a summary of the proceedings of the e-AGM of the Company held today i.e., Thursday, August 14, 2025, through video conference ('VC') / other audio visual means ('OAVM').

This is for your information and record please.

Thanking You.

Yours faithfully,
For **PI Industries Limited**

Shruti Joshi
Company Secretary and Compliance Officer

Encl: As above.



Summary of proceedings of the 78th e-AGM held on August 14, 2025 pursuant to Regulation 30 read with Schedule III of SEBI Listing Regulations, 2015

The 78th AGM of the Company was held on Thursday, August 14, 2025 at 10:30 a.m. (IST), through VC / OAVM facility.

Members present through VC & OAVM: 128

Mr. Narayan K Seshadri, Chairperson presided over the meeting and welcomed the members. The requisite quorum being present, the Chairperson called the meeting to order. The Chairperson informed the members that the Company had provided the facility of two-way video conferencing of the proceedings of this e-AGM which could be viewed live by the members by logging on the website of the Registrar, KFin Technologies Limited ('KFin').

The Chairperson introduced the Directors, the Chief Financial Officer & the Company Secretary. He informed that the authorized representatives of the Statutory Auditor, the Secretarial Auditor and the Scrutinizer, were also present virtually for this meeting. It was informed that, there were no observations, qualifications or comments either by the Statutory Auditors or the Secretarial Auditor in their respective reports having any adverse effect on the functioning of the Company and hence, their reports were not required to be read. With the permission of the shareholders, Notice convening this Annual General Meeting was taken as read.

The presence of the Chairperson of Audit Committee, Stakeholders Relationship Committee and Nomination & Remuneration Committee, was also confirmed.

With the permission of the shareholders, the notice convening this e-AGM was taken as read. The Chairperson informed that all the relevant documents and registers referred in the Notice calling the e-AGM pursuant to the Companies Act, 2013 ('the Act') read with Secretarial Standard on General Meetings, including the following, were made available for inspection by the shareholder's electronically on the website of KFin, throughout the duration of the e-AGM proceedings.

- a. Register of contracts or arrangements in which Directors are interested under Section 189 of the Act;
- b. Register of Directors and Key Managerial Personnel and their shareholding under Section 170 of the Act; and
- c. Certificate from Secretarial Auditor of the Company for the financial year 2024-25, certifying that the Employee Stock Option Scheme of the Company is being implemented in accordance with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021.

The Chairperson, then proceeded to address the shareholders on the performance of the Company for the financial year 2024-25 and the outlook for the next year. The same is enclosed herewith as **Annexure- A**.

The Chairperson informed the members that item No. 1 to 10 of the Notice have been voted by the members through remote e-voting from **August 10, 2025 to August 13, 2025**. The members present at the meeting who have not participated in remote e-voting, were allowed to cast their votes using e-voting platform of KFin.




It was informed that Mr. Ashish K Friends, Practicing Company Secretary, has been appointed by the Board of Directors of the Company as the Scrutinizer for scrutinizing the remote e-voting and e-voting process during the e-AGM in a fair and transparent manner.

Few of the members who had registered themselves as speaker shareholders were invited to express their views and queries. The queries raised by them were suitably replied to by the Chairperson, Mr. Mayank Singhal, Vice Chairperson and Managing Director and Mr. Sanjay Agarwal, Chief Financial Officer.

The following business items as set out in the Notice convening the 78th e-AGM were recommended for the consideration and approval of the members:

S. No.	Agenda Items	Type of Resolution
ORDINARY BUSINESSES:		
1.	To consider and adopt the financial statements (standalone and consolidated) of the Company for the financial year ended March 31, 2025, together with the reports of Board of Directors and Auditors thereon	Ordinary Resolution
2.	To confirm the payment of Interim Dividend of Rs. 6.00 per equity share of face value of Re. 1.00 each and to declare Final Dividend of Rs. 10.00 per equity share of face value of Re.1.00 each for the financial year ended March 31, 2025	Ordinary Resolution
3.	To appoint a director in place of Mr. Rajnish Sarna (DIN: 06429468), who retires by rotation and being eligible, offers his candidature for re-appointment	Ordinary Resolution
SPECIAL BUSINESSES:		
4.	Ratification of remuneration payable to Cost Auditor for the financial year 2025-26	Ordinary Resolution
5.	Appointment of M/s. Makarand M. Joshi & Co., Company Secretaries, (Firm Registration Number: P2009MH007000) as Secretarial Auditors of the Company	Ordinary Resolution
6.	Re-appointment of Mr. Mayank Singhal, (DIN: 00006651) as Vice Chairperson & Managing Director of the Company	Special Resolution
7.	Re-appointment of Mr. Rajnish Sarna, (DIN: 06429468) as Joint Managing Director of the Company	Special Resolution
8.	Re-appointment of Ms. Lisa J. Brown (DIN: 07053317), as an Independent Director	Special Resolution
9.	Appointment of Mr. Vegulaparanan Kasi Viswanathan (DIN: 01782934) as an Independent Director of the Company	Special Resolution
10.	Appointment of Dr. Tanjore Soundararajan Balganesh (DIN: 00648534) as a Non-Executive Non-Independent Director of the Company	Ordinary Resolution

The Chairperson thanked the Members for their continued support, valuable suggestions and for attending the 78th e-AGM. He informed the members that e-voting was kept open throughout the e-AGM and will remain open for 30 minutes after the conclusion of the meeting for the members who have not exercised their vote.




The Chairperson informed that the results of the e-voting will be announced within the stipulated time. Thereafter, the meeting concluded with vote of thanks to the Chair at 11:18 a.m. (IST).

This is for your information and records.

Thanking you,

Yours faithfully,
For **PI Industries Limited**

Shruti Joshi
Company Secretary and Compliance Officer



Annexure- A Chairman's Speech

"Good morning, Ladies and Gentlemen, esteemed shareholders, and members of the Board.

It is my privilege to welcome you to the **78th Annual General Meeting of PI Industries Limited**. On behalf of the Board of Directors, thank you for your continued trust in our Company.

Over the past year, the operating environment remained fluid—marked by shifting geopolitics, evolving trade policies, currency fluctuations, and tighter regulatory expectations. While inflation pressures eased, supply-chain realignments and policy changes required vigilance and agility. Through this backdrop, **PI delivered with resilience and clarity**, staying focused on innovation-led execution and disciplined growth.

Our theme for FY2024–25, "**Empowering through Innovation: Where Science Meets Life**," captures our intent: to turn scientific excellence into real-world solutions that improve lives, strengthen food security, and support a healthier planet. Your **Integrated Report for the year ended March 31, 2025** is with you; with your permission, I will highlight key outcomes.

Performance Highlights (FY2024–25)

- **Standalone:** Revenue of **₹75,712 million**, up **5.96% YoY**; operating margins **improved by 16.72% YoY** through portfolio mix and cost discipline; **Net Profit ₹18,665 million**, up **7.84% YoY**.
- **Consolidated:** Revenue of **₹79,778 million**, up **4.07% YoY**; **Net Profit ₹16,602 million**, a **1.27% YoY decline**, reflecting investments for future growth and the shape of the global cycle.
- **Shareholder returns:** An **interim dividend of ₹6.00 per share (600%)** has been paid; the Board **recommends a final dividend of ₹10.00 per share (1000%)** for your approval today.

Against global industry headwinds, **new growth drivers took hold**. Your Company launched **6 new products in Exports** and **7 new Agri brands in India**. Your Company **commercialized 7 new molecules**, including in **Electronic & Performance Chemicals**, reinforcing our position in these specialized, higher-value domains.

Innovation and Strategic Progress

Innovation remains our core engine. During the year, your Company **filed 44 patents** and advanced our **first proprietary A.I. (Active Ingredient) insecticide, PIOXANILIPROLE, now in Phase-3 trials** across key markets—a significant milestone in PI's innovation journey.



Your Company continues to broaden from an agri-sciences leader to a **diversified life-sciences powerhouse**, scaling across **pharmaceuticals, CRDMO, electronic chemicals, specialty chemicals, and biologicals**. Our **Health Sciences** vertical is gaining traction; we invested **~₹130 crore of capex in Pharma** to deepen integrated R&D-to-manufacturing capabilities.

Execution is increasingly digital. We are **embedding data tracking and AI-based tools in production**, strengthening quality, compliance, and speed. Partnerships with technology providers and innovators are helping us **shorten time-to-market** and **build differentiated business models**.

Portfolio Expansion in Biologicals

To diversify and reduce reliance on traditional chemistries and scale IP-rich, sustainable solutions, your Company **completed the acquisition of Plant Health Care PLC on August 20, 2024** through our wholly owned subsidiary. PHC brings **industry-leading peptide/protein technologies** and a strong presence across the **U.S., Mexico, Brazil, and the UK**, accelerating our biologicals platform and global reach.

Sustainability, ESG, and Governance

Where science meets life, **ESG is integral**—not an add-on. For the **second consecutive year**, PI was featured in the **S&P Global Sustainability Yearbook**, ranking in the **top three percent of chemical companies globally**. This reflects our focus on **responsible chemistry, optimal resource use, and low-carbon manufacturing**.

This year we advanced our disclosures by adopting **IFRS S1 and S2 standards** with a **“Climate-First” approach** in our Integrated Report. Across the value chain your Company continues to scale:

- **Green chemistry** and solvent recovery,
- **Energy optimization** and growing renewable integration,
- **Digital traceability**, lifecycle analysis, and **supply-chain decarbonization**,
- **Water stewardship, biodiversity, and product circularity** initiatives.

Strong **governance** underpins these efforts. Your Company is reinforcing risk management, data integrity, and transparency to stay ahead of evolving global regulations.



People and Culture

Our progress rests on the dedication of our people. I thank every colleague for living our values of **safety, ethics, and excellence**. We continue to strengthen **workforce diversity** and our **leadership pipeline**, investing in scientific talent, upskilling, and collaborative ways of working.

Outlook

As your Company looks ahead at FY2025–26 with **strategic momentum** and a **robust balance sheet** that allows long-term choices even in a volatile context. Our drivers are clear:

- **Agri-Sciences**: Differentiate through innovation, branded and specialty offerings in India, and premiumization to manage price pressure.
- **Biologicals**: Scale PHC's peptide platform and our own pipeline with disciplined market entry and partnerships.
- **Pharma CRDMO**: Convert strong customer interest into commercial momentum, leveraging our integrated R&D and compliant manufacturing.
- **Electronic & Specialty Chemicals**: Deepen our position in high-value chemistries aligned to global supply-chain realignment.

Our **adaptive go-to-market** strategy aligns with urbanization, income growth, and agri-tech adoption. The rising demand for safe, nutritious, and sustainably produced food is not only a growth vector but a catalyst for **collaborative innovation** across the value chain. We will continue to invest in **environment-compliant chemistries, automation, and end-to-end process integration** to lift productivity and resilience.

In short, we remain ahead of the curve—**innovation-led, sustainability-anchored, and execution-focused**—building on decades-long partnerships with global innovators and our recognized standing among the **top players in AgChem custom synthesis and manufacturing**.

Closing

To our shareholders, employees, customers, partners, and communities—**thank you**. Your support enables us to **grow responsibly and create enduring value**. We are confident about the road ahead and our role in shaping a more resilient, climate-aligned future where **science truly meets life**.

Thank you for your time and for your participation today.”